Amdocs Limited

The stock remains in a long-term downtrend, trading well below both the 200-day and 50-day moving averages. It is also sitting near the lower end of its 52-week range, which keeps the setup defensive until price can reclaim those longer-term trend lines.

Street sentiment stays constructive but cautious: consensus is Buy with a 4.2/5 score and an average target of about $81. Recent action has turned softer, with KeyBanc initiating at Sector Weight and CFRA cutting to Sell, while the target cluster has slipped to $71-$92.

Amdocs has beaten EPS in 6 of the last 7 quarters, including the last five reports in a row. The next print is set for 2026-08-05, with EPS estimated at 1.65; shareholders should watch whether management can keep the beat streak intact while guiding through slower earnings growth.

Recent insider activity leans mildly negative, but most of the table is noise from awards and zero-share entries. The only clear discretionary trade is a small sale by Matthew E. Smith, while the large Hortig share award is compensation-related rather than a market signal.

Profitability is solid, with gross margin at 37.8%, operating margin at 16.49%, and net margin at 11.81%. Growth is mixed: revenue rose 3.9% year over year, while earnings fell 11.6%, even as free cash flow stayed strong at $853 million and FCF yield reached 15.46%.

DOX looks like a cash-generative infrastructure software name rather than a high-growth peer, with a 0.394 beta and a valuation that still screens modest at 7.21x earnings. The market is pricing it below the analyst target band, but the multiple reflects slower earnings momentum and a net debt position.